Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efavaleukin alfa - Amgen

Next Previous
Drug Profile

Efavaleukin alfa - Amgen

Alternative Names: AMG 592; IL-2 mutein Fc fusion protein - Amgen

Latest Information Update: 04 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Antirheumatics; Cytoprotectives; Immunoglobulin Fc fragments; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus; Ulcerative colitis
  • Phase I/II Graft-versus-host disease
  • No development reported Inflammation
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 31 Oct 2024 Amgen completes a phase II trial in Ulcerative colitis (Treatment-experienced) in Argentina, Bulgaria, Denmark, Germany, Hungary, Japan, Korea, Republic of, Mexico, Poland, Romania, Switzerland, Turkey, the US, Spain, Italy, Austria, Netherlands, Belgium, Latvia, Slovakia, France, Finland, Greece (SC, Injection) (NCT05672199) (EudraCTNCT05672199)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in United Kingdom (SC)
  • 18 May 2024 Pharmacodynamics data from a phase I trial in Systemic lupus erythematous presented at the Digestive Disease Week 2024 (DDW-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top